http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2058388-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-15 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
filingDate | 2007-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2009-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2058388-A1 |
titleOfInvention | Non-conventional NKT cells for use in cancer therapy |
abstract | The invention relates to the use of CD1d-independent NKT cells, for the preparation of a pharmaceutical composition for treating a tumor in a patient. Said CD1d-independent NKT cells may be obtained by (a) culturing a population of T cells under conditions which suppress TGFβ signalling pathway, and (b) selecting the cells which exhibit at least one NK marker. |
priorityDate | 2007-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 124.